Fremanezumab
TV48125-CNS-30057
Phase 3 small_molecule terminated
Quick answer
Fremanezumab for Chronic Cluster Headache is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Chronic Cluster Headache
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated